Dr Goli Samimi: NCI Division of Cancer Prevention: Overview of Programs, Projects and Priorities in Ovarian Cancer Prevention
Special SW-TCRC & WIMR
Location:Westmead Institute for Medical Research Level 2 Conference Facility
Dr Goli Samimi, Program Director, Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health.
Dr Samimi’s research interests include molecular mechanisms of ovarian cancer etiology, circulating/shed DNA as a biomarker of ovarian cancer, and improving identification of high-risk individuals including BRCA1/2 mutation carriers.
Dr Samimi received her PhD in Biomedical Sciences from the University of California, San Diego, focusing on molecular mechanisms in ovarian cancer that conferred resistance to platinum-based chemotherapy. She then joined the Cancer Prevention Fellowship Program at the National Cancer Institute (NCI), focusing on molecular profiling of the tumor microenvironment in high-grade serous ovarian cancer. As part of the fellowship, she completed her Master of Public Health degree at Harvard School of Public Health. In 2011, Dr. Samimi joined the Garvan Institute of Medical Research in Sydney, Australia as Head of the Ovarian Cancer Research Group. Her lab focused on methylation in circulating DNA as a test for early detection of ovarian cancer, and the evaluation of a monoclonal antibody as a novel targeted therapeutic in high-grade serous ovarian cancer.
Morning tea provided at 11:30am